BioMarin Gears Up To Give Roctavian Another Go

Voxzogo Sales Could Exceed $100m

The company is aiming for an outcomes-based payment model in the US, while it is confident the gene therapy will fare better than some others have in Europe.

3-D Rendering Red Blood Cells
BioMarin is preparing to seek approval again for Roctavian in hemophilia A • Source: Shutterstock

Less than a year and a half after it received a surprise complete response letter (CRL) from the US Food and Drug Administration for Roctavian (valoctocogene roxaparvovec) in severe hemophilia A, BioMarin Pharmaceutical Inc. is now ready to reapproach regulators in the US as it awaits a decision on the gene therapy from European regulators and gets a sense of potential 2022 sales of Voxzogo (vosoritide), its recently approved drug for achondroplasia.

CEO Jean-Jacques Bienaimé provided the outlook for 2022 at BioMarin on 10 January at the J.P. Morgan Healthcare Conference.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.